Varian plans $250m share buy-back
This article was originally published in Clinica
Executive Summary
Radiotherapy specialist Varian Medical Systems is to repurchase $250m of its common stock under an accelerated share buy-back programme. The transaction will be funded primarily through the firm's revolving credit facility with Bank of America, which it has amended to increase borrowing capacity from $225m to $300m. Varian will receive approximately 3.8 million shares, or 85% of the shares to be repurchased based on its closing share price on 24 August ($55.20). The stock buy-back is Varian's second this year – it also repurchased $280m in shares in February (www.clinica.co.uk, 2 March 2011). The company recently reported third-quarter revenue growth of 12%, to $649.4m, driven by continued demand for newer products in its oncology systems and X-ray products units (www.clinica.co.uk, 28 July 2011). Net income was also up, at $98.6m, compared with $85.5m during last year's Q3. As of the end of the third quarter of fiscal year 2011, Varian had 119.1 million fully diluted shares outstanding.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.